These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 31302899

  • 1. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
    Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P.
    Clin Drug Investig; 2019 Oct; 39(10):979-990. PubMed ID: 31302899
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives.
    Sussman M, Benner J, Neumann P, Menzin J.
    Cephalalgia; 2018 Sep; 38(10):1644-1657. PubMed ID: 30142988
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling.
    Mistry H, Naghdi S, Brown A, Rees S, Madan J, Grove A, Khanal S, Duncan C, Matharu M, Cooklin A, Aksentyte A, Davies N, Underwood M.
    Health Technol Assess; 2024 Oct; 28(63):1-329. PubMed ID: 39365169
    [Abstract] [Full Text] [Related]

  • 6. Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK.
    Hollier-Hann G, Curry A, Onishchenko K, Akehurst R, Ahmed F, Davies B, Keyzor I.
    J Med Econ; 2020 Jan; 23(1):113-123. PubMed ID: 31578100
    [Abstract] [Full Text] [Related]

  • 7. Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
    Pozo-Rosich P, Poveda JL, Crespo C, Martínez M, Rodríguez JM, Irimia P.
    J Headache Pain; 2024 Mar 15; 25(1):40. PubMed ID: 38491460
    [Abstract] [Full Text] [Related]

  • 8. Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden.
    Mahon R, Lang A, Vo P, Huels J, Cooney P, Danyliv A, Vudumula U, Vadapalle S, Maniyar F, Goadsby PJ.
    Pharmacoeconomics; 2021 Mar 15; 39(3):357-372. PubMed ID: 33491167
    [Abstract] [Full Text] [Related]

  • 9. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, Lipton RB, Sullivan SD.
    J Med Econ; 2013 Jul 15; 16(7):877-87. PubMed ID: 23647483
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway.
    Hansson-Hedblom A, Axelsson I, Jacobson L, Tedroff J, Borgström F.
    J Headache Pain; 2020 Aug 12; 21(1):99. PubMed ID: 32787820
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of noninvasive vagus nerve stimulation for acute treatment of episodic migraine and role in treatment sequence strategies.
    Mwamburi M, Tenaglia AT, Leibler EJ, Staats PS.
    Am J Manag Care; 2018 Dec 12; 24(24 Suppl):S527-S533. PubMed ID: 30543270
    [Abstract] [Full Text] [Related]

  • 13. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine.
    Khanal S, Underwood M, Naghdi S, Brown A, Duncan C, Matharu M, Mistry H.
    J Headache Pain; 2022 Sep 16; 23(1):122. PubMed ID: 36114468
    [Abstract] [Full Text] [Related]

  • 14. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
    Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD.
    Clin Ther; 2013 Apr 16; 35(4):414-24. PubMed ID: 23522658
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment.
    Brown JS, Papadopoulos G, Neumann PJ, Friedman M, Miller JD, Menzin J.
    Headache; 2005 Sep 16; 45(8):1012-22. PubMed ID: 16109115
    [Abstract] [Full Text] [Related]

  • 16. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
    McCormack PL, Foster RH.
    Pharmacoeconomics; 2005 Sep 16; 23(12):1283-98. PubMed ID: 16336021
    [Abstract] [Full Text] [Related]

  • 17. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
    Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, Klatt J, Cheng S, Zhang F, Wen S, Ritter S, Lenz RA, Mikol DD.
    Cephalalgia; 2020 Jan 16; 40(1):28-38. PubMed ID: 31816249
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland.
    Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu ZJ.
    Eur J Neurol; 2013 May 16; 20(5):773-80. PubMed ID: 23278954
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.